StevenGrossman

FDA After the Election—Part 2: Leadership and Change

For part 1 of this series regarding budget, click here. Apart from an occasional reference, FDA is not part of the campaign dialogue leading up to the November 6 nationwide U.S. election. Yet, FDA Matters believes that FDA will be strongly impacted by the election’s outcomes.  Part 1 of “FDA After the Election” concentrated on the agency’s budget situation. …

FDA After the Election—Part 2: Leadership and Change Read More »

FDA’s E-Mail Scandal: First Impressions

According to the New York Times, FDA collected more than 75,000 employee e-mails in an effort to identify leaks of confidential trade secret information. At some point, a narrow, possibly legitimate inquiry into a handful of scientists at the Center for Devices and Radiological Health (CDRH) turned into a massive e-mail surveillance of selected individuals and …

FDA’s E-Mail Scandal: First Impressions Read More »

Mid-Year 2012 Report on FDA: Opportunities, Threats and Accomplishments

So much is going on at FDA right now, that it is difficult to pick just one topic for this week’s FDA Matters. Instead, we are going to take a quick tour of some “hot spots” at FDA and how they might affect the agency over the remainder of the year and beyond. Please read on…there …

Mid-Year 2012 Report on FDA: Opportunities, Threats and Accomplishments Read More »